NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

Had Linda decided to stay with CRL and contract CRL from the beginning (as what she said at the ASM they are planning todo this year 2023 and perhaps and hopefully this already happened), then this would have cost far less. After the CRL contract, the RA's could have approved DCVAXL based on the manufacturing contract with CRL, and within a year after data lock stock price would go to $ 15-$20 then sell 100 million shares THEN build a CDMO OWNED by NWBO AND start new trials.

This would have been the best path forward after data lock.

The reason why she did not is that IF DCVAXL were to be disapproved by the RA's then at least she can keep her own CDMO and sell it exactly as she did with Cognate.

And THAT is the real uncomfortable truth.